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Abstract
Optimizing the in vivo stability of positron emission tomography (PET) tracers is of critical importance to cancer diagnosis. In
the case of
64Cu-labeled monoclonal antibodies (mAb), in vivo behavior and biodistribution is critically dependent on the
performance of the bifunctional chelator used to conjugate the mAb to the radiolabel. This study compared the in vivo
characteristics of
64Cu-labeled TRC105 (a chimeric mAb that binds to both human and murine CD105), through two
commonly used chelators: 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA). Flow cytometry analysis confirmed that chelator conjugation of TRC105 did not affect its CD105
binding affinity or specificity. PET imaging and biodistribution studies in 4T1 murine breast tumor-bearing mice revealed
that
64Cu-NOTA-TRC105 exhibited better stability than
64Cu-DOTA-TRC105 in vivo, which resulted in significantly lower liver
uptake without compromising the tumor targeting efficiency. In conclusion, this study confirmed that NOTA is a superior
chelator to DOTA for PET imaging with
64Cu-labeled TRC105.
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Introduction
Radiolabeled antibodies have been used in the clinic for
diagnostic and therapeutic applications for over 40 years [1,2].
Monoclonal antibody (mAb)-based positron emission tomography
(PET), termed ‘‘immunoPET’’, is an attractive method for non-
invasive tumor detection since this strategy combines the high
sensitivity of PET with the high antigen specificity of mAbs. If the
mAb is used for systemic therapy of cancer, either as a single agent
or in combination with other anti-cancer drugs, immunoPET with
the radiolabeled mAb can be used for tumor detection, patient
selection, as well as treatment planning [3].
Commonly used PET isotopes for antibody labeling include
64Cu (t1/2=12.7 h),
86Y( t 1/2=14.7 h),
89Zr (t1/2=3.3 d),
124I( t 1/2
=4.2 d), among others [4]. Currently,
64Cu is the most widely used
isotope for immunoPET, partly due to its wide availability, low cost,
and versatile chemistry. The Emax of 656 keV for its positron
emission, which is comparable to that of
18F and lower than that of
124I, can produce PET images with good spatial resolution. In
addition, there are several radioisotopes of Cu available, which
allow for both diagnostic imaging (with
60/61/62/64Cu) and
therapeutic applications (with
64/67Cu) [5].
One of the key requirements for accurate PET imaging with
64Cu-labeled mAbs is that the tracer should be sufficiently stable
during the imaging period, since PET scanners detect the
distribution of
64Cu instead of the mAb itself. Over the years,
many bifunctional chelators have been investigated for
64Cu-
labeling, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraa-
cetic acid (DOTA) [6,7], 1,4,7-triazacyclononane-1,4,7-triacetic
acid (NOTA) [8–11], 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-
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N,N9,N0,N--tetraacetic acid (BAT) [13], 4,11-bis(carboxymethyl)-
1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A) [14,15],
1,8-diamino-3,6,10,13,16,19-hexaazabicyclo(6,6,6)eicosane (Dia-
msar) [16,17], among many others [4,18].
CD105 (endoglin), a 180 kDa disulfide-linked homodimeric
transmembrane protein, is one of the most suitable markers for
tumor angiogenesis [19,20]. In contrast to CD31, which is
expressed on both normal and proliferating vasculature, CD105
is only over-expressed on proliferating tumor endothelial cells and
CD105 immunohistochemistry (IHC) is the accepted standard for
detecting proliferating vessels (i.e. neovessels) within tumors. Not
surprisingly, high microvessel density (MVD) of CD105-expressing
vessels correlates with poor prognosis and/or survival in more
than 10 solid tumor types [19,21]. TRC105 is a human/murine
chimeric IgG1 mAb which binds to both human and murine
CD105 [22]. The murine parent antibody of TRC105 (SN6j) has
demonstrated anti-cancer efficacy in animal tumor models [20].
Recently, a multicenter Phase 1 first-in-human dose-escalation
trial of TRC105 was completed in the United States and Phase 2
therapy trials are underway in ovarian, prostate, bladder, liver,
and breast cancer [23].
We recently reported the first PET imaging of CD105
expression using
64Cu-DOTA-TRC105 in 4T1 murine breast
tumor-bearing mice [24]. Prominent and persistent tracer uptake
in the 4T1 tumor was observed. In addition, blocking experiments
with unlabeled TRC105, control studies with
64Cu-DOTA-
cetuximab (an isotype matched chimeric mAb that binds to the
human epidermal growth factor receptor [25,26]), as well as ex
vivo histology all confirmed the in vivo target specificity of
64Cu-
DOTA-TRC105. In order to further improve the in vivo behavior
of
64Cu-labeled TRC105, this study investigated the performance
of TRC105 conjugated to
64Cu using a NOTA chelator (i.e.
64Cu-
NOTA-TRC105) through PET imaging and biodistribution
studies. Through direct comparison with data obtained from our
previous study of
64Cu-DOTA-TRC105 [24], we evaluated the
effect of bifunctional chelators (i.e. DOTA and NOTA) on the in
vivo behavior of the PET tracers.
Results
In Vitro Investigation of NOTA-TRC105
The chemistry for NOTA and DOTA conjugation to TRC105
was similar (Figure 1). NOTA conjugation of TRC105 did not
alter its CD105 binding affinity, as evidenced by fluorescence-
activated cell sorting (FACS) analysis (Figure 2). At non-antigen-
saturating conditions, FACS analysis of human umbilical vein
endothelial cells (HUVECs, CD105-positive [24]) revealed no
observable difference between TRC105 and NOTA-TRC105 at
1 mg/mL or 5 mg/mL. The binding to HUVECs was CD105-
specific, as neither TRC105 nor NOTA-TRC105 bound to
CD105-negative MCF-7 cells. These data were comparable to our
previous studies using DOTA-TRC105 [24], with neither NOTA
or DOTA conjugation affecting the antigen binding avidity or
specificity of TRC105.
64Cu-Labeling
64Cu-labeling including final purification using PD-10 columns
took 80610 min (n=5). The decay-corrected radiochemical yield
was .85% based on 25 mg of TRC105 (DOTA-TRC105 or
NOTA-TRC105) per 37 MBq of
64Cu, and the radiochemical
purity was .98%. The specific activity of
64Cu-NOTA-TRC105
was about 3.0 GBq/mg protein, virtually identical to that of
64Cu-
DOTA-TRC105 [24], assuming complete recovery of NOTA-
TRC105 after size exclusion chromatography. Based on the
specific activity of
64Cu (,5% of the theoretical value of 254 Ci/
mmol) and the amount of NOTA-TRC105 used for radiolabeling,
it was calculated that there were 0.4260.04 (n=3)
64Cu ion per
molecule of TRC105.
Small Animal PET Studies
The time points of 4, 24, and 48 h post-injection (p.i.) were
chosen for serial PET scans after intravenous tracer injection,
based on our previous studies with
64Cu-DOTA-TRC105 and
other
64Cu-labeled mAbs [6,24,25,27]. Coronal slices containing
the 4T1 tumor are shown in Figure 3A and representative PET/
CT fused images of a mouse at 48 h p.i. of
64Cu-NOTA-TRC105
Figure 1. NOTA and DOTA conjugation of TRC105.
doi:10.1371/journal.pone.0028005.g001
PET of CD105
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ROI analysis are shown in Figure 3B&D. Consistent with our
previous findings of radiolabeled antibodies, the uptake of
64Cu-
NOTA-TRC105 in the liver (due to hepatic clearance and
potential trans-chelation of
64Cu) and blood pool (due to long
circulation half-life of the antibody) was prominent at early time
points and gradually declined over time. Liver uptake of
64Cu-
NOTA-TRC105 was 11.961.4, 8.561.8, and 6.760.6 percent-
age injected dose per gram of tissue (%ID/g) at 4, 24, and 48 h p.i.
respectively, while the radioactivity in the blood was 16.261.9,
10.762.0, and 8.360.9%ID/g at 4, 24, and 48 h p.i. respectively
(n=3; Figure 3B). Uptake of
64Cu-NOTA-TRC105 in the 4T1
tumor was clearly visible at 4 h p.i. and plateaued after 24 h p.i.
(7.562.7, 11.461.9, and 13.061.2%ID/g at 4, 24, and 48 h p.i.
respectively; n=3; Figure 3B&D), indicating antigen specific
binding.
Comparing the two TRC105-based tracers, tumor uptake of
64Cu-NOTA-TRC105 increased over time while that of
64Cu-
DOTA-TRC105 peaked at 24 h p.i. and slightly decreased at 48 h
p.i. At the 48 h time point, the difference between tumor uptake of
the two tracers was statistically significant (P,0.05; n=3;
Figure 3D).
Biodistribution Studies
Following the terminal PET scans at 48 h p.i., all mice were
euthanized for biodistribution studies. In addition, a separate
group of three mice were injected with
64Cu-NOTA-TRC105 and
euthanized at 24 h p.i. for biodistribution studies (Figure 4A).
The uptake of
64Cu-NOTA-TRC105 in the liver and spleen was
significantly lower than that of
64Cu-DOTA-TRC105 at 24 h p.i.,
while the radioactivity in the blood pool showed an opposite trend,
suggesting significantly better in vivo stability and prolonged
circulation half-life of
64Cu-NOTA-TRC105. Uptake of
64Cu-
NOTA-TRC105 in all tissues (except blood) was lower than that
in the 4T1 tumor at 24 h p.i. However, the 4T1 tumor uptake of
the two tracers was similar at 24 h p.i., based on both region-of-
interest (ROI) analysis of PET data and biodistribution results.
Comparing the biodistribution of
64Cu-NOTA-TRC105 and
64Cu-DOTA-TRC105 at 48 h p.i. (Figure 4B), blood radioac-
tivity was still prominent for
64Cu-NOTA-TRC105, which was
significantly higher than that of
64Cu-DOTA-TRC105. The 4T1
tumor uptake of
64Cu-NOTA-TRC105 was also higher than that
of
64Cu-DOTA-TRC105 at 48 h p.i., suggesting higher stability of
64Cu-NOTA-TRC105 than
64Cu-DOTA-TRC105. Interestingly,
the uptake of
64Cu-DOTA-TRC105 dropped significantly in all
major organs from 24 h p.i. to 48 h p.i., while the uptake of
64Cu-
NOTA-TRC105 remained stable in all organs. This phenomenon
may be attributed to the longer circulation half-life of
64Cu-
NOTA-TRC105, which resulted in sufficient amount of the tracer
circulating in the blood available for antigen binding, whereas
64Cu-DOTA-TRC105 was gradually cleared with little surplus
tracer available within the circulation. In addition, the difference
in stability of
64Cu-NOTA and
64Cu-DOTA complexes certainly
played a role.
At both 24 h and 48 h p.i., tumor uptake of
64Cu-NOTA-
TRC105 was higher than all major organs in the mice, thus
providing excellent tumor contrast (Figure 3&4). For
64Cu-
DOTA-TRC105, such tumor contrast was only achieved at 48 h
p.i., after the majority of initial liver and spleen uptake of the
tracer cleared over time. Overall, the quantification results
obtained from biodistribution studies and PET scans matched
very well, confirming that quantitative ROI analysis of non-
invasive microPET scans accurately reflected the distribution of
PET tracers in vivo.
Discussion
In vivo stability of
64Cu-chelates has been hotly debated over
the last decade, and many chelators have been designed and
evaluated for
64Cu-labeling of various targeting ligands [4]. Based
on available literature data, the in vitro thermodynamic stability
constants of Cu-DOTA and Cu-NOTA are similar at 25uC
[28,29]. However, these constants were measured in a simple in
vitro chemical system, which does not represent the biological
environment in vivo. Furthermore, attaching a mAb to the
chelator will significantly improve the stability of the
64Cu-chelator
complex, since trans-chelation of Cu requires conformational
change of the chelator, which is much more difficult when a mAb
is attached. In this study, we evaluated the in vivo behavior of two
PET tracers,
64Cu-DOTA-TRC105 and
64Cu-NOTA-TRC105,
and compared the effect of the bifunctional chelator on
64Cu/
tracer biodistribution.
The two conjugates showed similar tumor targeting efficiency at
24 h p.i., indicating that different chelators do not significantly
impact tracer uptake in the tumor. However, tracer uptake in
many normal organs exhibited significant differences, including
the liver, spleen, and kidneys. Since liver is one of the major organs
for
64Cu trans-chelation [30], liver uptake of
64Cu-DOTA-
Figure 2. Flow cytometry analysis of TRC105 and NOTA-TRC105 in HUVECs (CD105-positive) and MCF-7 (CD105-negative) cells at
different concentrations.
doi:10.1371/journal.pone.0028005.g002
PET of CD105
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64Cu-NOTA-TRC105 at
24 h p.i. Lung uptake of
64Cu-NOTA-TRC105 was also much
higher than that of
64Cu-DOTA-TRC105 at 48 h p.i., which is
likely due to the prolonged circulation half-life of
64Cu-NOTA-
TRC105 (as the lung is a very well-perfused organ). Although
tumor uptake of the two tracers was similar at 24 h p.i., uptake of
64Cu-DOTA-TRC105 dropped slightly from 24 h to 48 h p.i.
while the uptake of
64Cu-NOTA-TRC105 remained relatively
stable. One possible explanation for this finding is the acidic
environment in the tumor tissue. It has been suggested that the
kinetic stability of a Cu complex is a function of the change of its
degree of protonation as a response to changes in pH, and Cu-
NOTA was found to be more stable than Cu-DOTA at pH 4.6
[11]. Although the tumor pH value may not be as low as 4.6 in
many cases, the typically acidic microenvironment of the tumor
[31] may be one cause for a decrease in tumor uptake of
64Cu-
DOTA-TRC105 over time.
Recently, an elegant study compared the effect of several
bifunctional chelators on the biodistribution of a
64Cu-labeled
antibody [11], which concluded that thermodynamic stability of
64Cu-chelator complexes did not significantly influence tumor
uptake of the tracer. However, there were significant differences in
tracer concentration in other tissues, including those involved in
clearance of the radioimmunoconjugate (e.g., liver and spleen).
Our findings are in agreement with these data, as tumor uptake of
the two tracers was similar while the liver/spleen uptake was quite
different for
64Cu-NOTA-TRC105 and
64Cu-DOTA-TRC105.
Taken together the findings from these two studies and various
other literature reports, we conclude that NOTA is one of the best
chelators for
64Cu-labeling of macromolecules, proteins, or
nanomaterials [8–10,32].
One key challenge in antibody labeling is to minimize the
potential interference with its antigen binding affinity/specificity.
There is only one lysine residue in each of the complementarity-
determining regions (CDRs) of TRC105 [20], which has a total of
,1400 amino acid residues and ,70 lysines. Therefore, the
possibility of DOTA/NOTA conjugation at the lysine residue
within the CDR is extremely low, which was confirmed by FACS
analysis at several non-antigen-saturating conditions (Figure 2).
To confirm that tumor uptake of TRC105-based imaging probes
measured by non-invasive imaging techniques was indeed CD105
specific, various control experiments (e.g. blocking study with
unconjuagted TRC105, as well as the use of cetuximab as an
isotype-matched control), in vitro/ex vivo studies (e.g. FACS and
histological analysis), as well as biodistribution and ex vivo imaging
studies were performed for validation purposes [24,33,34].
The primary focus of this study was to compare
64Cu-labeled
TRC105 through DOTA and NOTA, and we found that NOTA
was superior to DOTA in many aspects as detailed above.
However, even though the in vivo kinetic stability of Cu-DOTA is
lower than Cu-NOTA, DOTA is a universal chelator which can
complex a wide variety of both imaging and therapeutic
radioisotopes. The same DOTA-mAb conjugate can therefore
be employed for both imaging and therapeutic applications, with
Figure 3. Small animal PET imaging of 4T1 tumor-bearing mice. A. Serial coronal PET images at 4, 24, and 48 h post-injection of
64Cu-NOTA-
TRC105. Tumors are indicated by arrowheads. B. Time-activity curves of tumor, liver, blood, and muscle after intravenous injection of
64Cu-NOTA-
TRC105 into 4T1 tumor-bearing mice (n=3) C. Representative PET/CT images of
64Cu-NOTA-TRC105 in 4T1 tumor-bearing mice at 48 h post-
injection. D. Comparison of the 4T1 tumor uptake of
64Cu-NOTA-TRC105 and
64Cu-DOTA-TRC105. *: P,0.05.
doi:10.1371/journal.pone.0028005.g003
PET of CD105
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netics and tumor targeting efficacy. With future clinical translation
and cGMP (current good manufacturing practice) compliance in
mind, using the same mAb conjugate for both imaging and
therapeutic applications (i.e. ‘‘theranostics’’) is undoubtedly more
advantageous than using two different conjugates. If the major
goal of a future study is to reduce the radiation dose to the liver,
NOTA is the chelator of choice for
64Cu. If the same antibody will
be used for radioimmunotherapy applications (e.g. with
90Y and/
or
177Lu), DOTA may be a better option.
In conclusion, we investigated the properties of
64Cu-NOTA-
TRC105 both in vitro and in vivo. Compared with our previous
study of
64Cu-DOTA-TRC105,
64Cu-NOTA-TRC105 was more
stable in vivo which is in agreement with previous literature
reports [11,35]. We found that the nature of the bifunctional
chelator affected the biodistribution of
64Cu-labeled mAb to some
extent. However, tumor targeting efficacy was not significantly
impacted by the bifunctional chelator. Since TRC105 is already in
Phase 2 trials and therapeutic efficacy has been shown in various
animal tumor models and certain cancer patients, clinical
translation of
64Cu-NOTA-TRC105 is desirable where it may
be used for patient selection/stratification, as well as evaluating the
pharmacokinetics, tumor targeting efficacy, dose optimization, and
dose interval of TRC105 and TRC105-based cancer therapeutics
in the clinic.
Materials and Methods
Reagents
TRC105 was provided by TRACON pharmaceuticals Inc. (San
Diego, CA). AlexaFluor488-conjugated secondary antibody was
purchased from Jackson Immunoresearch Laboratories, Inc. (West
Figure 4. Biodistribution studies in 4T1 tumor-bearing mice. A. Biodistribution of
64Cu-NOTA-TRC105 and
64Cu-DOTA-TRC105 at 24 h post-
injection (n=3). B. Biodistribution of
64Cu-NOTA-TRC105 and
64Cu-DOTA-TRC105 at 48 h post-injection (n=3). *: P,0.05.
doi:10.1371/journal.pone.0028005.g004
PET of CD105
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nane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was purchased from
Macrocyclics, Inc. (Dallas, TX) and Chelex 100 resin (50–100
mesh) was purchased from Sigma-Aldrich (St. Louis, MO). Water
and all buffers were of Millipore grade and pre-treated with
Chelex 100 resin to ensure that the aqueous solution was heavy-
metal free. PD-10 desalting columns were purchased from GE
Healthcare (Piscataway, NJ).
64Cu was produced via a
64Ni(p,n)
64Cu reaction using a cyclotron at the University of
Wisconsin-Madison.
Cell Lines and Animal Model
All animal studies were conducted under a protocol approved
by the University of Wisconsin Institutional Animal Care and Use
Committee (M02239). 4T1 murine breast cancer, MCF-7 human
breast cancer, and HUVECs were obtained from the American
Type Culture Collection (ATCC, Manassas, VA) and cultured as
previously described [24,33,34]. Cells were used for in vitro and in
vivo experiments when they reached ,80% confluence. To
generate the 4T1 tumor model, four- to five-week-old female
Balb/c mice (Harlan, Indianapolis, IN) were each subcutaneously
injected with 2610
6 cells, suspended in 100 mL of 1:1 mixture of
RPMI 1640 and matrigel (BD Biosciences, Franklin lakes, NJ)
[36]. The tumor sizes were monitored every other day and mice
were used for in vivo experiments when the tumor diameter
reached 6–8 mm (typically less than 2 weeks after inoculation).
NOTA Conjugation and
64Cu-Labeling
NOTA conjugation was carried out at pH 9.0, with the ratio of
p-SCN-Bn-NOTA:TRC105 being 25:1, the same as that used
previously for DOTA-TRC105 (Figure 1). NOTA-TRC105 was
purified using PD-10 columns. For radiolabeling,
64CuCl2
(74 MBq) was diluted in 300 mL of 0.1 M sodium acetate buffer
(pH 6.5) and added to 50 mg of NOTA-TRC105. The reaction
mixture was incubated for 30 min at 40uC with constant shaking.
64Cu-NOTA-TRC105 was purified using PD-10 columns with
phosphate-buffered saline (PBS) as the mobile phase. The
radioactive fractions containing
64Cu-NOTA-TRC105 were
collected and passed through a 0.2 mm syringe filter for in vivo
experiments.
Flow Cytometry
The immunoreactivity of TRC105 and NOTA-TRC105 to
HUVECs (high CD105 expression [37,38]) and MCF-7 (CD105-
negative [38]) cells were evaluated by flow cytometry. Cells were
harvested and suspended in cold PBS with 2% bovine serum
albumin (BSA) at a concentration of 5610
6 cells/ml. These cells
were incubated with TRC105 or NOTA-TRC105 (1 or 5 mg/ml)
for 30 min at room temperature (RT), washed three times with
cold PBS, and centrifuged at 1,000 rpm for 5 min. The cells were
then incubated with AlexaFluor488-labeled goat anti-human IgG
for 30 min at RT. Afterwards, the cells were washed and analyzed
by flow cytometry using a BD FACSCalibur 4-color analysis
cytometer equipped with 488 nm and 633 nm lasers (Becton-
Dickinson, San Jose, CA) and FlowJo analysis software (Tree Star,
Inc., Ashland, OR).
PET Imaging and Biodistribution Studies
PET and PET/CT scans at various time points p.i., image
reconstruction, and ROI analysis were performed using a
microPET/microCT Inveon rodent model scanner (Siemens
Medical Solutions USA, Inc.) as described previously [34]. Each
tumor-bearing mouse was injected with 5–10 MBq of
64Cu-
NOTA-TRC105 via tail vein and 3–15 min static PET scans were
performed. Quantitative data were presented as %ID/g. Biodis-
tribution studies were carried out after the last PET scans to
validate the PET results.
Statistical Analysis
Quantitative data were expressed as mean 6 SD. Means were
compared using Student’s t-test. P values,0.05 were considered
statistically significant.
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